PDF(Pubmed)
Abstract：
UNASSIGNED: To investigate the efficacy and safety of microwave ablation (MWA) assisted by ultrasound fusion imaging (FI) for primary and secondary liver cancers with a diameter of 3-7 cm.
UNASSIGNED: A retrospective analysis was conducted on patients with primary and secondary liver cancers (3-7 cm) who underwent MWA with ultrasound FI assistance in our hospital from April 2020 to May 2022. Technical success, technique efficacy, local tumor progression (LTP), major complication, intrahepatic distant recurrence (IDR), and overall survival (OS) were assessed during the follow-up period. In addition, the ablation results of tumors between the medium-sized group (3.1-5.0 cm) and large-sized group (5.1-7.0 cm) were compared.
UNASSIGNED: 31 patients with 35 primary and secondary liver cancers were treated with MWA assisted by ultrasound FI. Complete ablation was achieved in 34 lesions with a technical success rate of 97.1%. Major complications occurred in 6.5% of patients (2/31), while no ablation-related deaths were reported. The median follow-up time of this study was 24 months (range:10 to 35 months). The technique efficacy rate was 97.1% (34/35), with LTP occurring in three lesions at a rate of 8.8% (3/34). The incidence of IDR was 38.7% (12/31) and the 2-year cumulative OS rate reached 96.7%. Moreover, there were no statistical differences in technique efficacy rate (p=0.286), LTP rate (p=0.328), major complication rate (p=0.503), IDR (p=0.857), and OS (p=0.118) between medium-sized group and large-sized group.
UNASSIGNED: Ultrasound FI-assisted MWA has the potential to be an effective and safe therapeutic strategy for primary and secondary liver cancers ranging from 3-7 cm in size.
UNASSIGNED: A retrospective analysis was conducted on patients with primary and secondary liver cancers (3-7 cm) who underwent MWA with ultrasound FI assistance in our hospital from April 2020 to May 2022. Technical success, technique efficacy, local tumor progression (LTP), major complication, intrahepatic distant recurrence (IDR), and overall survival (OS) were assessed during the follow-up period. In addition, the ablation results of tumors between the medium-sized group (3.1-5.0 cm) and large-sized group (5.1-7.0 cm) were compared.
UNASSIGNED: 31 patients with 35 primary and secondary liver cancers were treated with MWA assisted by ultrasound FI. Complete ablation was achieved in 34 lesions with a technical success rate of 97.1%. Major complications occurred in 6.5% of patients (2/31), while no ablation-related deaths were reported. The median follow-up time of this study was 24 months (range:10 to 35 months). The technique efficacy rate was 97.1% (34/35), with LTP occurring in three lesions at a rate of 8.8% (3/34). The incidence of IDR was 38.7% (12/31) and the 2-year cumulative OS rate reached 96.7%. Moreover, there were no statistical differences in technique efficacy rate (p=0.286), LTP rate (p=0.328), major complication rate (p=0.503), IDR (p=0.857), and OS (p=0.118) between medium-sized group and large-sized group.
UNASSIGNED: Ultrasound FI-assisted MWA has the potential to be an effective and safe therapeutic strategy for primary and secondary liver cancers ranging from 3-7 cm in size.
摘要：
■探讨超声融合成像（FI）辅助微波消融（MWA）对直径3-7cm的原发性和继发性肝癌的疗效和安全性。
■对2020年4月至2022年5月在我院接受MWA超声FI辅助治疗的原发性和继发性肝癌（3-7cm）患者进行了回顾性分析。技术上的成功,技术功效，局部肿瘤进展（LTP），主要并发症,肝内远处复发（IDR），在随访期间评估总生存期(OS).此外,比较中型组(3.1~5.0cm)和大型组(5.1~7.0cm)的肿瘤消融结果.
■31例35例原发性和继发性肝癌患者在超声FI辅助下接受MWA治疗。在34个病灶中实现了完全消融，技术成功率为97.1％。主要并发症发生率为6.5%(2/31),而无消融相关死亡报告.这项研究的中位随访时间为24个月（范围：10至35个月）。技术有效率为97.1%(34/35),三个病变中发生LTP的比率为8.8%(3/34)。IDR发生率为38.7%(12/31),2年累积OS率达96.7%。此外，技术疗效率无统计学差异(p=0.286)，LTP率（p=0.328），主要并发症发生率（p=0.503），IDR（p=0.857），中型组和大型组之间的OS（p=0.118）。
■超声FI辅助MWA有可能成为3-7厘米大小的原发性和继发性肝癌的有效和安全的治疗策略。
■对2020年4月至2022年5月在我院接受MWA超声FI辅助治疗的原发性和继发性肝癌（3-7cm）患者进行了回顾性分析。技术上的成功,技术功效，局部肿瘤进展（LTP），主要并发症,肝内远处复发（IDR），在随访期间评估总生存期(OS).此外,比较中型组(3.1~5.0cm)和大型组(5.1~7.0cm)的肿瘤消融结果.
■31例35例原发性和继发性肝癌患者在超声FI辅助下接受MWA治疗。在34个病灶中实现了完全消融，技术成功率为97.1％。主要并发症发生率为6.5%(2/31),而无消融相关死亡报告.这项研究的中位随访时间为24个月（范围：10至35个月）。技术有效率为97.1%(34/35),三个病变中发生LTP的比率为8.8%(3/34)。IDR发生率为38.7%(12/31),2年累积OS率达96.7%。此外，技术疗效率无统计学差异(p=0.286)，LTP率（p=0.328），主要并发症发生率（p=0.503），IDR（p=0.857），中型组和大型组之间的OS（p=0.118）。
■超声FI辅助MWA有可能成为3-7厘米大小的原发性和继发性肝癌的有效和安全的治疗策略。
